In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies.
Phospholipidosis (PLD) is characterized by the excessive intracellular accumulation of phospholipids. It is well established that a large number of cationic amphiphilic drugs have the potential to induce PLD. In the present study, we describe two facile in vitro methods to determine the PLD-inducing potential of a molecule. The first approach is based on a recent study by (Sawada et al., 2005, Toxicol. Sci. 83, 282-292) in which 17 genes were identified as potential biomarkers of PLD in HepG2 cells. To confirm the utility of this gene panel, we treated HepG2 cells with PLD-positive and -negative compounds and then analyzed gene expression using real-time PCR. Our initial analysis, which used a single dose of each drug, correctly identified five of eight positive compounds and four of four negative compounds. We then increased the doses of the three false negatives (amiodarone, tamoxifen, and loratadine) and found that the changes in gene expression became large enough to correctly identify them as PLD-inducing drugs. Our results suggest that a range of concentrations should be used to increase the accuracy of prediction in this assay. Our second approach utilized a fluorescently labeled phospholipid (LipidTox) which was added to the media of growing HepG2 cells along with compounds positive and negative for PLD. Phospholipid accumulation was determined using confocal microscopy and, more quantitatively, using a 96-well plate assay and a fluorescent plate reader. Using an expanded set of compounds, we show that this assay correctly identified 100% of PLD-positive and -negative compounds. Dose-dependent increases in intracellular fluorescent phospholipid accumulation were observed. We found that this assay was less time consuming, more sensitive, and higher throughput than gene expression analysis. To our knowledge, this study represents the first validation of the use of LipidTox in identifying drugs that can induce PLD.
Nioi
Paul
P
The Schering-Plough Research Institute, 181 Passaic Avenue, Summit, New Jersey 07901, USA. paul.nioi@spcorp.com
Perry
Brad K
BK
Wang
Er-Jia
EJ
Gu
Yi-Zhong
YZ
Snyder
Ronald D
RD
D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D064420:Drug-Related Side Effects and Adverse Reactions; D005453:Fluorescence; D005456:Fluorescent Dyes / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects*; D020869:Gene Expression Profiling; D005819:Genetic Markers; D006801:Humans; D008064:Lipidoses / Q000139:chemically induced* / Q000378:metabolism; D018613:Microscopy, Confocal; D004364:Pharmaceutical Preparations / Q000145:classification; D010743:Phospholipids / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D015203:Reproducibility of Results; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018675:Toxicity Tests / Q000379:methods*
D004338:Drug Combinations; D005456:Fluorescent Dyes; D005819:Genetic Markers; D004364:Pharmaceutical Preparations; D010743:Phospholipids; D012333:RNA, Messenger